Spero Therapeutics Inc. [NASDAQ: SPRO] stock went on an upward path that rose over 5.11% on Wednesday, amounting to a one-week price increase of more than 9.09%. The company report on August 10, 2023 at 4:05 PM that Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update.
SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023.
Over the last 12 months, SPRO stock rose by 63.64%. The one-year Spero Therapeutics Inc. stock forecast points to a potential upside of 78.41. The average equity rating for SPRO stock is currently 2.20, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $77.07 million, with 52.57 million shares outstanding and 42.74 million shares in the current float. Compared to the average trading volume of 302.89K shares, SPRO stock reached a trading volume of 2969017 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Spero Therapeutics Inc. [SPRO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SPRO shares is $6.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SPRO stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Spero Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 23, 2022.
The Average True Range (ATR) for Spero Therapeutics Inc. is set at 0.09, with the Price to Sales ratio for SPRO stock in the period of the last 12 months amounting to 1.42. The Price to Book ratio for the last quarter was 1.38, with the Price to Cash per share for the same quarter was set at 1.45. Price to Free Cash Flow for SPRO in the course of the last twelve months was 6.42 with Quick ratio for the last quarter at 5.10.
SPRO Stock Performance Analysis:
Spero Therapeutics Inc. [SPRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.09. With this latest performance, SPRO shares dropped by -5.26% in over the last four-week period, additionally sinking by -4.64% over the last 6 months – not to mention a rise of 63.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPRO stock in for the last two-week period is set at 55.43, with the RSI for the last a single of trading hit 62.88, and the three-weeks RSI is set at 51.35 for Spero Therapeutics Inc. [SPRO]. The present Moving Average for the last 50 days of trading for this stock 1.4355, while it was recorded at 1.3300 for the last single week of trading, and 1.6548 for the last 200 days.
Insight into Spero Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Spero Therapeutics Inc. [SPRO] shares currently have an operating margin of -73.07 and a Gross Margin at +96.82. Spero Therapeutics Inc.’s Net Margin is presently recorded at -95.55.
Return on Total Capital for SPRO is now -31.33, given the latest momentum, and Return on Invested Capital for the company is -41.52. Return on Equity for this stock declined to -56.53, with Return on Assets sitting at -31.37. When it comes to the capital structure of this company, Spero Therapeutics Inc. [SPRO] has a Total Debt to Total Equity ratio set at 8.75. Additionally, SPRO Total Debt to Total Capital is recorded at 8.05, with Total Debt to Total Assets ending up at 5.33. Long-Term Debt to Equity for the company is recorded at 6.53, with the Long-Term Debt to Total Capital now at 6.00.
Reflecting on the efficiency of the workforce at the company, Spero Therapeutics Inc. [SPRO] managed to generate an average of -$1,326,143 per employee. Receivables Turnover for the company is 26.08 with a Total Asset Turnover recorded at a value of 0.33.Spero Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.10 and a Current Ratio set at 5.10.
SPRO Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SPRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Spero Therapeutics Inc. go to 36.90%.
Spero Therapeutics Inc. [SPRO] Institutonal Ownership Details
The top three institutional holders of SPRO stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in SPRO stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in SPRO stock with ownership which is approximately 5.7381%.
